First in human phase I study of TQB2103, a Claudin18.2 (CLDN18.2) targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Zhejiang Cancer Hospital, Henan Cancer Hospital, Xuzhou Central Hospital, Central South University, Hunan Cancer Hospital, Third Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Xi'an Jiaotong University, Fudan University Shanghai Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, University of Electronic Science and Technology of China, Mianyang Central Hospital, Zhujiang Hospital, Southern Medical University, West China Hospital of Sichuan University, Qilu Hospital of Shandong University, Southwest Medical University, Affiliated Hospital of Southwest Medical University
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410814358